...
首页> 外文期刊>Oncology reports >Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.
【24h】

Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.

机译:选择性环氧合酶2抑制剂在口腔鳞状细胞癌中抑制增殖和诱导凋亡的差异作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Cyclooxygenase-2 (COX-2), an enzyme that catalyzes the synthesis of prostaglandins, is made inducible by various stimuli such as inflammation. Although COX-2 is commonly overexpressed in a variety of premalignant and malignant conditions including oral leukoplakia and squamous cell carcinoma, relatively little research has compared the effects of various COX-2 inhibitors (celecoxib, NS-398, nimesulide and meloxicam). Therefore, we investigated the effects of four different selective COX-2 inhibitors on the growth of KB cells, derived from oral squamous cell carcinoma (OSCC) and its mechanisms. Celecoxib and NS-398 strongly suppressed the proliferation of KB cells at 10-100 microM, whereas nimesulide and meloxicam are less potent proliferation inhibitors. Only celecoxib induced apoptosis of the KB cells, as detected on the basis of DNA fragmentation, caspase-3/7 activation and cleaved poly(ADP-ribose) polymerase (PARP) fragmentation. All four COX-2 inhibitors increased COX-2 protein expression but suppressed prostaglandin (PG) E2 production in the KB cells, suggesting that the pro-apoptotic effect of celecoxib was unrelated to the inhibition of COX-2. Mechanistically, a high level of p53 protein and a low level of multidrug-resistant protein 1 (MRP1) and breast cancer resistant protein (BCRP) mRNA in KB cells with celecoxib may explain the differential effect of these selective COX-2 inhibitors in KB cells. Taken together, celecoxib is a good therapeutic candidate for treating OSCC through the suppression of cell proliferation and the induction of apoptosis in a COX-2 independent manner.
机译:环氧合酶2(COX-2)是一种催化前列腺素合成的酶,可通过各种刺激(例如炎症)来诱导。尽管COX-2通常在包括口腔白斑和鳞状细胞癌在内的各种恶变前和恶性疾病中过表达,但相对较少的研究比较了各种COX-2抑制剂(塞来昔布,NS-398,尼美舒利和美洛昔康)的作用。因此,我们研究了四种不同的选择性COX-2抑制剂对源自口腔鳞状细胞癌(OSCC)的KB细胞生长的影响及其机制。塞来昔布和NS-398在10-100 microM时强烈抑制了KB细胞的增殖,而尼美舒利和美洛昔康是效力较低的增殖抑制剂。根据DNA片段化,caspase-3 / 7激活和裂解的聚(ADP-核糖)聚合酶(PARP)片段检测,只有塞来昔布诱导KB细胞凋亡。所有四种COX-2抑制剂均增加了KB细胞中COX-2蛋白的表达,但抑制了前列腺素(PG)E2的产生,这表明塞来昔布的促凋亡作用与COX-2的抑制作用无关。从机理上讲,KB细胞中含有塞来昔布的p53蛋白水平高,多药耐药蛋白1(MRP1)和乳腺癌耐药蛋白(BCRP)mRNA的水平低可能解释了这些选择性COX-2抑制剂对KB细胞的不同作用。总之,塞来昔布是通过抑制细胞增殖和以独立于COX-2的方式诱导凋亡来治疗OSCC的良好候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号